Valeo Pharma joins the Innovative Medicines Canada Association

Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHIF) (FSE:VP2) said it has been accepted for admission as a full member of the Innovative Medicines Canada (IMC) Association, the representative body for Canada’s innovative pharmaceutical industry.

With 47 members across the spectrum of small, mid-size, and large national and multi-national companies, the IMC association plays a central advocacy role in all major issues related to the pharmaceutical industry, including price reform and the pan-Canadian rare disease strategy, amongst others.

WATCH: Valeo Pharma closes oversubscribed financing while getting Redesca and RedescaHP covered in Ontario

“We are pleased to welcome Valeo Pharma into the association and look forward to working with them on delivering better healthcare solutions. Canadians deserve and should expect timely access to the latest innovative medicines and treatment therapies, and Valeo will be an important IMC partner in achieving this goal”, said Pamela Fralick, president of IMC.

“We are proud to be admitted to Innovative Medicines Canada and we commend the tireless work of IMC in ensuring our industry thrives in Canada. Valeo’s vision of building a foundational Canadian pharmaceutical company by driving therapeutic innovation to patients in need, is very well aligned with IMC’s vision of ensuring that Canadians have access to the innovative treatments they need”, Valeo Pharma CEO Steve Saviuk said in a statement.

“We believe it is important for the future development of Valeo to increase our involvement alongside recognized industry leaders to ensure key healthcare issues receive the attention they deserve. Joining IMC will allow us to participate with our peers, government, healthcare professionals and other related stakeholders in building a stronger life sciences ecosystem for the benefit of all Canadians”, added Valeo president and chief operating officer Frederic Fasano.

Contact the author at [email protected]

Follow him on Twitter @Cal_Proac

Story by ProactiveInvestors